Glucose (Viaflo) Baxter (Glucose)

Glucose (Viaflo) Baxter is indicated for clinical situations that require rapid carbohydrate supplementation or fluid balance restoration.

• Treatment of hypoglycemia in patients unable to take oral glucose.
• Intravenous fluid and electrolyte replacement in dehydration or shock.
• Support during surgical procedures to maintain blood glucose levels.
• Management of metabolic disorders where glucose infusion is required.

When administered intravenously, Glucose (Viaflo) Baxter may be associated with a range of observed effects.

Common

• Transient rise in blood glucose levels.
• Mild nausea or vomiting.
• Local irritation or pain at the infusion site.

Serious

• Severe hyperglycemia with osmotic diuresis.
• Allergic reactions including rash, itching, or anaphylaxis.
• Fluid overload or pulmonary edema in patients with cardiac dysfunction.

Healthcare professionals should observe specific precautions when prescribing or administering Glucose (Viaflo) Baxter to ensure patient safety.

• Verify blood glucose levels before and during infusion.
• Adjust infusion rate in patients with renal or cardiac impairment.
• Use aseptic technique to prevent contamination.
• Monitor electrolytes, especially sodium and potassium, during prolonged therapy.
• Avoid rapid infusion in neonates and infants.
• Assess for signs of fluid overload in susceptible individuals.

Glucose (Viaflo) Baxter can interact with certain medications, requiring attention to avoid adverse outcomes.

Avoid

• Co-administration with high-dose insulin without glucose monitoring.
• Simultaneous infusion of hypertonic saline solutions that may exacerbate hyperglycemia.
• Use with drugs that contain potassium in high concentrations without electrolyte monitoring.

Use with caution

• Concurrent use of diuretics that affect fluid balance.
• Administration alongside corticosteroids that raise blood glucose.
• Combination with beta‑adrenergic agonists that can increase glucose production.